Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acura Pharmaceuticals Inc ACUR

Healthcare Drug Manufacturers - Specialty & Generic
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the... see more

Recent & Breaking News (GREY:ACUR)

Acura Pharmaceuticals Receives 2015 Frost & Sullivan North American Opioid Oral Abuse Deterrence Technology Innovation Award

Marketwired November 10, 2015

Acura Pharmaceuticals Receives 2015 Frost & Sullivan North American Opioid Oral Abuse Deterrence Technology Innovation Award

Marketwired November 10, 2015

Acura Earns Accolades from Frost & Sullivan for Developing a Novel Technology Platform to Prevent the Abuse of Opioid-based Medication through Oral Administration

PR Newswire November 9, 2015

Acura Pharmaceuticals Announces Third Quarter 2015 Financial Results

Marketwired November 4, 2015

Acura Pharmaceuticals to Host Third Quarter 2015 Financial Results Conference Call on November 5, 2015

Marketwired October 28, 2015

Acura Receives $2.5 Million Milestone Payment From Egalet Corporation

Marketwired October 12, 2015

Acura Pharmaceuticals Meets NASDAQ's Continuing Listing Requirement

Marketwired September 16, 2015

Egalet Corporation Launches Acura Pharmaceuticals' OXAYDO(TM)

Marketwired September 9, 2015

Acura Pharmaceuticals Announces 1-for-5 Reverse Stock Split

Marketwired August 24, 2015

Acura Pharmaceuticals Announces Second Quarter 2015 Financial Results

Marketwired August 3, 2015

Acura Pharmaceuticals Announces Second Quarter 2015 Financial Results

Marketwired August 3, 2015

Acura Pharmaceuticals to Host Second Quarter 2015 Financial Results Conference Call on August 4, 2015

Marketwired July 27, 2015

Acura Pharmaceuticals to Host Second Quarter 2015 Financial Results Conference Call on August 4, 2015

Marketwired July 27, 2015

Acura Pharmaceuticals to Raise Approximately $7.6 Million From Institutional Healthcare Investors

Marketwired July 1, 2015

Acura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx(TM) Abuse Deterrent Technology

Marketwired June 29, 2015

Acura Pharmaceuticals Partners Its Methamphetamine Resistant Impede(R) Technology

Marketwired June 16, 2015

Acura Pharmaceuticals Announces First Quarter 2015 Financial Results

Marketwired May 4, 2015

Acura Pharmaceuticals to Host First Quarter 2015 Financial Results Conference Call on May 5, 2015

Marketwired April 21, 2015

Acura Pharmaceuticals to Develop Abuse Deterrent Hydrocodone With Acetaminophen Tablets With Limitx(TM) Technology

Marketwired April 9, 2015

Acura Pharmaceuticals Reports Successful Topline Results From Nexafed(R) Extended-Release Clinical Study

Marketwired March 23, 2015